TGF-β Suppresses Tumor Progression in Colon Cancer by Inhibition of IL-6 trans-Signaling
暂无分享,去创建一个
Stefan Wirtz | Susanne Strand | Peter R. Galle | Markus F. Neurath | Ralf Kiesslich | Alexei Nikolaev | Stefan Rose-John | Christoph Schramm | R. Kiesslich | M. Neurath | P. Galle | S. Rose-John | H. Lehr | S. Wirtz | M. Blessing | S. Strand | T. Kishimoto | S. Huber | C. Schramm | C. Becker | K. Yoshizaki | N. Nishimoto | Hiroaki Ito | Samuel Huber | Massimo C. Fantini | Christoph Becker | Tadamitsu Kishimoto | Kazuyuki Yoshizaki | Manfred Blessing | M. Fantini | A. Nikolaev | J. Burg | Norihiro Nishimoto | Hans A. Lehr | Jürgen Burg | Hiroaki Ito
[1] T. S. Wilkinson,et al. Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. , 2001, Immunity.
[2] David C. Lee,et al. Tumor Necrosis Factor-α Converting Enzyme (TACE) Regulates Epidermal Growth Factor Receptor Ligand Availability* , 2002, The Journal of Biological Chemistry.
[3] P. Wallace,et al. Central role of IL-6 receptor signal-transducing chain gp130 in activation of L-selectin adhesion by fever-range thermal stress. , 2004, Immunity.
[4] A. Roberts,et al. Factors involved in the differentiation of TGF-beta-producing cells from naive CD4+ T cells: IL-4 and IFN-gamma have opposing effects, while TGF-beta positively regulates its own production. , 1998, Journal of immunology.
[5] S. Takeno,et al. Prognostic significance of CD8+ T cell and macrophage peritumoral infiltration in colorectal cancer. , 2003, Oncology reports.
[6] J. Baselga,et al. TACE is required for the activation of the EGFR by TGF‐α in tumors , 2003 .
[7] Markus F Neurath,et al. IL-6 trans-signaling: the heat is on. , 2004, Immunity.
[8] J. Wang,et al. Soluble interleukin 6 receptor (sIL-6R) mediates colonic tumor cell adherence to the vascular endothelium: a mechanism for metastatic initiation? , 2002, The Journal of surgical research.
[9] M. Tomlinson,et al. TGF‐β1 down‐regulates Th2 development and results in decreased IL‐4‐induced STAT6 activation and GATA‐3 expression , 2000 .
[10] L. Pelosio,et al. Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery. , 2002, Clinical immunology.
[11] B. Jenkins,et al. Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STAT-mediated trefoil gene activation in gp130 mutant mice , 2002, Nature Medicine.
[12] T. Naka,et al. The paradigm of IL-6: from basic science to medicine , 2002, Arthritis research.
[13] K. Kinzler,et al. Mutational inactivation of transforming growth factor beta receptor type II in microsatellite stable colon cancers. , 1999, Cancer research.
[14] A. Roberts,et al. Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF‐β , 1999, The EMBO journal.
[15] A. Jemal,et al. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. , 2003, Journal of the National Cancer Institute.
[16] R. Coffey,et al. Production of transforming growth factors by human colon cancer lines. , 1986, Cancer Research.
[17] G. Ciliberto,et al. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. , 1997, Immunity.
[18] M. Neurath,et al. Constitutive p40 promoter activation and IL-23 production in the terminal ileum mediated by dendritic cells. , 2003, The Journal of clinical investigation.
[19] S. Rose-John,et al. A bioactive designer cytokine for human hematopoietic progenitor cell expansion , 1997, Nature Biotechnology.
[20] P. Schirmacher,et al. Impairment of TGF-beta signaling in T cells increases susceptibility to experimental autoimmune hepatitis in mice. , 2003, American journal of physiology. Gastrointestinal and liver physiology.
[21] M. Neurath,et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn disease and experimental colitis in vivo , 2000, Nature Medicine.
[22] P. Heinrich,et al. Soluble receptors for cytokines and growth factors: generation and biological function. , 1994, The Biochemical journal.
[23] L. Glimcher,et al. Lineage commitment in the immune system: the T helper lymphocyte grows up. , 2000, Genes & development.
[24] S. Akira. Roles of STAT3 defined by tissue-specific gene targeting , 2000, Oncogene.
[25] J. Grötzinger,et al. The Soluble Interleukin‐6 Receptor a , 1995, Annals of the New York Academy of Sciences.
[26] M. Neurath,et al. The role of Th1/Th2 polarization in mucosal immunity , 2002, Nature Medicine.
[27] S. Szabo,et al. Transcriptional regulation of Th1/Th2 polarization. , 2000, Immunology today.
[28] Yuan‐Chang Chung,et al. Serum interleukin‐6 levels reflect the disease status of colorectal cancer , 2003, Journal of surgical oncology.
[29] Simon A. Jones,et al. The soluble interleukin 6 receptor: mechanisms of production and implications in disease , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[30] Kenneth M. Murphy,et al. Decision making in the immune system: The lineage decisions of helper T cells , 2002, Nature Reviews Immunology.
[31] Takuji Tanaka,et al. A novel inflammation‐related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate , 2003, Cancer science.
[32] A. Hoeflich,et al. Interleukin-6 stimulates clonogenic growth of primary and metastatic human colon carcinoma cells. , 2000, Cancer letters.
[33] T. Ohkusa,et al. Promotion of colorectal neoplasia in experimental murine ulcerative colitis. , 1996, Gut.